In the article by Desai et al. (Sept. 11 issue)1 on mavacamten in patients with nonobstructive hypertrophic cardiomyopathy (HCM), the results for both coprimary end points — the change from baseline to week 48 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better health status) — narrowly missed statistical significance with P values of 0.07 and 0.06, respectively.
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy. Reply / Desai, M.Y., Owens, A.T., Olivotto, I.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - ELETTRONICO. - 394:(2026), pp. 616-618. [10.1056/NEJMc2514559]
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy. Reply
Olivotto, Iacopo
2026
Abstract
In the article by Desai et al. (Sept. 11 issue)1 on mavacamten in patients with nonobstructive hypertrophic cardiomyopathy (HCM), the results for both coprimary end points — the change from baseline to week 48 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better health status) — narrowly missed statistical significance with P values of 0.07 and 0.06, respectively.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
